According to Fortune Business Insights, the global life science software market size was valued at USD 17.69 billion in 2025 and is projected to grow from USD 19.48 billion in 2026 to USD 43.19 billion by 2034, exhibiting a CAGR of 10.50% during the forecast period from 2026 to 2034. North America accounted for a 34.30% market share in 2025.
Life science software is increasingly being integrated into workflows covering clinical trials, research and development, supply chain management, pharmacovigilance, regulatory compliance, and commercial engagement. The software enables companies to work with large datasets while improving operational efficiency and supporting data-driven decisions.
The market is also influenced by increasing investments, mergers and acquisitions, and partnerships throughout the global life sciences sector. According to the source, worldwide life sciences M&A investment reached USD 191 billion through December 10, 2023, compared with USD 142 billion in 2022.
Cloud deployment is gaining importance because it allows organizations to work with large datasets and leverage modern computing capabilities. At the same time, on-premise solutions remain relevant because life sciences organizations handle sensitive patient, medical, research, and manufacturing information.
For detailed market insights: https://www.fortunebusinessinsights.com/life-science-software-market-109261
The increasing use of data analytics is a significant trend in the life science software market. Analytics can support scientific innovation, analytical decision-making, collaboration, and transparency within highly regulated environments.
Applied AI, industrialized ML, edge computing, and cloud technologies are also being integrated into life sciences workflows. According to the source, life sciences enterprises allocate around 45% of their technology investments to prominent analytics-linked technologies such as applied AI, industrialized ML, and edge and cloud computing.
Generative AI is creating new applications across the life sciences sector. These technologies can support customized content, sales efficiency evaluation, drug-like molecule design, synthetic biology applications, and data preparation for model training.
The source notes that approximately more than 90% of medtech and biopharma companies expect generative AI to have a positive business impact in coming years, while around 66% of life sciences firms are using it to test ideas and develop use cases.
Marketing automation is identified as a key factor supporting market growth. Life sciences companies are adopting automated email tracking, workflows, analytics dashboards, data collection, and customer engagement tools to improve marketing activities.
Data-driven marketing can help organizations generate higher-quality leads, improve customer engagement, reduce customer churn, personalize content, and align sales and marketing activities. Life science software vendors are consequently developing marketing and commercialization solutions to support revenue generation.
The acceleration of digital transformation is another important growth factor. Companies are increasingly using AI, ML, cloud technologies, and digital manufacturing capabilities to monitor and analyze production processes and manage supply requirements.